Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor
- 18 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Cancer Conference Journal
- Vol. 10 (2), 112-115
- https://doi.org/10.1007/s13691-021-00472-4
Abstract
SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLCJournal of Thoracic Oncology, 2020
- Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case reportImmunotherapy, 2020
- Clinicopathologic Characteristics of BRG1-Deficient NSCLCJournal of Thoracic Oncology, 2020
- SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasJournal of Thoracic Oncology, 2019
- Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumorAnnals of Oncology, 2019
- SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomasNature Genetics, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic typeNature Genetics, 2014
- SWI/SNF nucleosome remodellers and cancerNature Reviews Cancer, 2011
- Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition SyndromeAmerican Journal of Human Genetics, 2010